Weekly Funding Opportunities

[Med Research]

PhRMA Foundation: Health Outcomes Research<https://urldefense.com/v3/__http://www.phrmafoundation.org/2018-awards/research-starter-grants/health-outcomes-informatics/__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKXHjILAc$ >
The PhRMA Foundation supports the research and early-career endeavors of scientists in drug discovery and development. To that end, the foundation welcomes applications for its Pharmacoeconomics, Real World Data and Health Outcomes Program (Health Outcomes Research). The program supports a broad spectrum of issues related to healthcare delivery, from studies evaluating the effectiveness of a pharmaceutical intervention, to the impact of reimbursement policies on outcomes of care, to the development and use of patient-level real-world data and tools to perform patient-based assessments, to analyses of ways in which results of Health Outcomes Research are disseminated to providers or consumers to encourage behavior change. Grants of up to $100,000 will be awarded to support individuals beginning independent research careers in health outcomes at the faculty level in support of:

  *   Pharmacoeconomics — Research evaluating the behavior of individuals, organizations, and markets concerning use of pharmaceutical products, services, and programs.
  *   Clinical Outcomes Assessment (COA) — Research dedicated to the value assigned to duration of life as modified by the impairment of physical, social, and psychological functional states, symptoms, satisfaction, perceptions, and opportunities influenced by disease, injury, treatment, or policy.
  *   Patient-level Real-World Data and Analytic Tools — The evolving and increasing use and evaluation of technologies, analyses, and patient-level prospective databases (e.g., electronic medical records, health insurance claims data, registries, patient health-networks, patient health status monitoring) to assist in better understanding disease and interventions.
Due February 3, 2021. Med-RA deadline to receive draft documents: January 21.

Music and Health: Understanding And Developing Music Medicine (R21 / R01 Clinical Trial Optional)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-099.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKjH8SxZ4$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-21-100.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKrqAokTQ$ >
These FOAs are intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders.
R21 Due February 16, 2021; February 16, 2022; and February 16, 2023. Med-RA deadline to receive draft documents for February 2021 due date: February 3.
R01 Due February 5, 2021; February 5, 2022; and February 5, 2023. Med-RA deadline to receive draft documents for February 2021 due date: January 25.

Alzheimer’s Drug Discovery Foundation: Prevention Beyond the Pipeline<https://urldefense.com/v3/__https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKSqw1Gbc$ >
The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. The Prevention Pipeline RFP supports:

  1.  Studies of Cognitive Decline and Risk Reduction: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under “Expectations and Evaluation”.
  2.  Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer’s or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper<https://urldefense.com/v3/__https://alzres.biomedcentral.com/articles/10.1186/s13195-016-0200-3__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK1DSTmoc$ >). Methods may include randomized trials or epidemiology.
  3.  Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to supplements or medications. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here.<https://urldefense.com/v3/__https://www.alzdiscovery.org/research-and-grants/funding-opportunities/capa-consortium__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKqxrmK1M$ >
Type of therapy: Novel, repurposed and repositioned drugs, as well as natural products and devices will be considered. Therapeutic modalities of interest include small molecules, peptides, antibodies, gene therapies, antisense oligonucleotides, and stem cells. Other non-pharmacologic interventions, such as diet, meditation, and exercise, will not be considered.
Drug mechanisms or modes of action: Novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia are considered high priority. These include, but are not limited to:

  *   Epigenetics
  *   Inflammation
  *   Mitochondrial & metabolic function
  *   Neuroprotection
  *   Proteostasis
  *   Synaptic activity and neurotransmitters
  *   Vascular function
  *   Other mechanisms and modes of action related to the biology of aging (e.g. senescent cells)
  *   Other novel mechanisms or modes of action that are supported by compelling evidence demonstrating a rational biological connection to the disease process
  *   Please note: Anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) and cholinesterase inhibitor proposals will not be considered
Grants of up to $3,000,000 will be awarded for clinical trials based on stage and scope of research.
Letter of intent due February 5, 2021; May 28, 2021; October 1, 2021. Med-RA deadline to receive draft documents for February due date: January 25.

Klingenstein-Simons Fellowship Awards in Neuroscience<https://urldefense.com/v3/__https://klingenstein.org/esther-a-joseph-klingenstein-fund/neuroscience/applying/__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKfKo8QHE$ >
The Klingenstein-Simons Fellowship supports early-career investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders. Several areas within neuroscience are of particular interest:

  *   Cellular and molecular neuroscience. Studies of the mechanisms of neuronal excitability and development, and of the genetic basis of behavior.
  *   Neural systems. Studies of the integrative function of the nervous system.
  *   Translational research. Studies designed to improve our understanding of the causes, prevention, diagnosis, and treatment of neurological and psychiatric disorders.
$225,000 over three years, no IDC.
Due February 15, 2021. Med-RA deadline to receive draft documents: February 2.

American Psychological Foundation: Walter Katkovsky Research Grants<https://urldefense.com/v3/__https://www.apa.org/apf/funding/katkovsky-research-grants?tab=1__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKDpHn5dk$ >
Up to $20,000. APF Walter Katkovsky Research Grants support research on the general topic of psychotherapy. Research proposals should be directed to questions and hypotheses designed to improve our understanding based on theory or methods of how psychotherapy promotes behavioral, emotional, or cognitive changes. While the ultimate goal of the research should be to inform the psychotherapy process, its specific focus may be limited to an underlying assumption, hypothesis, or questions; and the actual design may be “clinical” or “experimental” in terms of subjects and procedures. That is, the research design may be a simulation of some aspect of the psychotherapy process (e.g., learning or exposure trials) and subjects may or may not be classified as “patients”.
Due March 1, 2021. Med-RA deadline to receive draft documents: February 16.

Enabling Discovery through GEnomics (EDGE)<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21546/nsf21546.htm__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKBg9ZvLU$ >
Through the Enabling Discovery through GEnomics (EDGE) program, the National Science Foundation (NSF) and the National Institutes for Health (NIH) support research to advance understanding of comparative and functional genomics. The EDGE program supports the development of innovative tools, technologies, resources, and infrastructure that advance biological research focused on the identification of the causal mechanisms connecting genes and phenotypes. The EDGE program also supports functional genomic research that addresses the mechanistic basis of complex traits in diverse organisms within the context (environmental, developmental, social, and/or genomic) in which they function. These goals are essential to uncovering the rules that underlie genomes-to-phenomes relationships and predict phenotype, an area relevant to Understanding the Rules of Life: Predicting Phenotype<https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/big_ideas/life.jsp__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK8tYeBGI$ >, one of the 10 Big Ideas<https://urldefense.com/v3/__https://www.nsf.gov/news/special_reports/big_ideas/index.jsp__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK6-5uskQ$ > for NSF investment. The goals also support the NHGRI priority to establish the roles and relationships of all genes and regulatory elements in pathways, networks, and phenotypes. The EDGE program will accept proposals to two submission tracks:
FUNCTIONAL GENOMIC TOOLS (FGT) TRACK: Proposals submitted to this track should aim to develop and provide proof-of-concept tests of functional genomic tools and infrastructure to enable direct tests of hypotheses about gene function in diverse species for which such tools and infrastructure are presently unavailable. Investigators may use taxonomic, question-based, and/or technology-based strategies to develop tools and approaches that will be employed by larger communities of researchers. Projects may include instrumentation development followed by proof-of-concept testing in the context of developing functional genomic tools to enable direct tests of gene function.
COMPLEX MULTIGENIC TRAITS (CMT) TRACK: Proposals submitted to this track should include hypothesis-driven research that advances understanding of the relationship between genomes and complex multi-genic traits, toward the goal of predicting phenotypes across diverse contexts, including environmental, developmental, social, and/or genomic contexts. Successful proposals may include the development of theory and/or analytical approaches to achieve the scientific goal. The EDGE program recognizes that many of the traits of interest to biologists are quantitative in nature and are controlled by many genes of small effect and that understanding complex traits requires systems-level analysis of the underlying gene regulatory networks that goes beyond linking individual genes with said traits. Submissions to the COMPLEX MULTIGENIC TRAITS TRACK should emphasize the contribution of genome-wide factors that impact expression of a phenotype.
NSF-BSF Proposals: The EDGE program will accept proposals for the joint NSF/US-Israel Binational Science Foundation (BSF) collaborative research opportunity. More information can be found in the Dear Colleague Letter at: https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20094__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKH5u_T50$  and subsequent replacements.
Due March 16, 2021 and February 17, 2022. Med-RA deadline to receive draft documents for March due date: March 3.

NSF Dear Colleague Letter: IMAGiNE FG: Functional Genomics<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21034/nsf21034.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKVO6CjGc$ >
The Division of Integrative Organismal Systems (IOS) has developed a thematic research focus entitled Integrating Mechanisms of Adaptation with Genes in Networks and across Environments (IMAGiNE). A Dear Colleague Letter (DCL), NSF 20-044<https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20044__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKoVyuO68$ > IMAGiNE: 2020: Organisms in a Dynamic Environment – was issued that is still current and actively encouraging submission of proposals addressing how organism-environment interactions determine the emergence of complex traits. This DCL (IMAGiNE FG: Functional Genomics) complements and extends the IMAGiNE theme. Here, the focus is to encourage research on the organismal mechanisms, analytical frameworks, and biological theories that advance our understanding of the connection between an organism’s genome and its phenotype, i.e., functional genomics. In an effort to develop strategies to move the field of functional genomics forward the National Academies of Sciences, Engineering, and Medicine (NASEM) in Washington, DC recently held a workshop entitled “Next Steps for Functional Genomics.” [1]<https://urldefense.com/v3/__https://www.nsf.gov/pubs/2021/nsf21034/nsf21034.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click*1__;Iw!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKVQjRK8A$ > The goals of the workshop were to determine the current state of research in functional genomics and to identify the factors limiting advancements in this field. This IMAGiNE FG: Functional Genomics DCL acts on the proceedings of the NASEM workshop by encouraging the submission of proposals that include the dual criteria of research that (1) is relevant to any of the programs in the Integrative Organismal Systems Core Programs solicitation NSF 21-506<https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf21506__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKSGAqe38$ > (, the Plant Biotic Interactions (PBI) solicitation NSF 20-576<https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf20576__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAK4DQqIWc$ >, or the Plant Genome Research Program (PGRP) solicitation NSF 21-507<https://urldefense.com/v3/__https://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf21507__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKnrR6FXU$ > and (2) addresses obstacles to moving the field of functional genomics forward as identified in the NASEM workshop report.
Proposals accepted any time. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor.

Mood Disorders in People Living with HIV: Mechanisms and Pathways (R21 / R01 Clinical Trial Optional)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-117.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKWDnYFSA$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-116.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKqB9oNF8$ >
The purpose of these Funding Opportunity Announcements (FOAs) is to support studies to better understand the underlying mechanisms and interplay of biological, psychosocial and structural factors contributing to mood disorders in people living with HIV.
Due March 10, 2021. Med-RA deadline to receive draft documents: February 25.

Congressionally Directed Medical Research Programs
Breast Cancer Research Program<https://urldefense.com/v3/__https://cdmrp.army.mil/funding/bcrp__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKDVBsf_c$ >
Breakthrough Award Levels 1 and 2
Pre-application (letter of intent): March 11, 2021. Application: March 25, 2021.
Breakthrough Award Level 3
Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021.
Breakthrough Award Level 4
Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021.
Era of Hope Scholar Award
Pre-application (letter of intent): March 11, 2021. Application: March 25, 2021. Confidential letters of recommendation: June 25, 2021.
Pre-application (preproposal): March 12, 2021. Invited full application: June 23, 2021.
Med-RA deadline to receive draft documents for the above pre-application due dates: March 1.

Improving Health Disparities in Alcohol Health Services (R01 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-001.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKOUus_po$ >
This Funding Opportunity Announcement solicits applications on health disparities and health services-related research focusing on: 1) access to treatment, 2) making treatment more appealing, 3) costs, and 4) dissemination and implementation. All applications are expected to emphasize health disparities in addition to the other four areas of focus mentioned above.
Due March 15, 2021. Med-RA deadline to receive draft documents: March 2.

Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01 – Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-014.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKK6TkGWQ$ >
This funding opportunity is intended to support research that enhances the understanding of the pathophysiology and epidemiology of cardiovascular disease among individuals with Type 1 Diabetes Mellitus (T1DM) and advances the development of interventions to reduce CVD risk among these individuals. The overall goal is to develop evidence-based guidelines to prevent or reduce CVD complications of T1DM across the lifespan. This funding opportunity will support epidemiologic studies to refine risk assessment, mechanistic trials to enhance understanding of the pathophysiology of CVD in T1DM, and small clinical trials that could inform the future development of larger trials focused on preventing or reducing the CVD complications of T1DM.
Due March 15, 2021 and October 15, 2021. Med-RA deadline to receive draft documents for March due date: March 2.

New Approaches to Identify Neurogenesis and Study its Dynamics in Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-006.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKHKxy9oo$ >
The goal of this Funding Opportunity Announcement is to support research on novel approaches and/or innovative expansion of existing approaches to identify the presence of neurogenesis and study its dynamics in brain aging and AD/ADRD.
Due June 17, 2021. Med-RA deadline to receive draft documents: June 7.

Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-032.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKa92YdKs$ >
The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.
Due June 22, 2021; June 22, 2022; and June 22, 2023. Med-RA deadline to receive draft documents for June 2021 due date: June 9.

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-092.html__;!!PhOWcWs!lN5ItPSa6_qyHPIHys-ovLhW-JiivHBQbomd8mSlWnkEabRTk9rIjuhAfsaQbESAQl3ky6XrYbAKQ3c5LII$ >
The purpose of this Funding Opportunity Announcement is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.
Due July 26, 2021; July 25, 2022; and July 25, 2023. Med-RA deadline to receive draft documents for July 2021 due date: July 13.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.



-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210108/95d32e63/attachment.html>